PBMs likely to be a focus in 118th Congress
Medtech regulation outlook in 2023: Faster approvals among priorities as AI moves to fore
FDA reports initial 'no signal' for stroke risk with Pfizer boosters
Celularity warns 'substantial portion' of staff about possible layoffs after reviewing cell therapy strategy
*please scroll down for all the latest news*
